REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$20.79
+0.68%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$20.80
From 52W high+0.00%
Volume346364.00
Market cap$1.97B
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$20.80
From 52W high
+0.00%
Volume
346364.00
Market cap
$1.97B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−6.9x
P/E (TTM)
—
RSI (14)
80.4
MomentumView details →
1D Return
+0.68%
YTD Return
+104.42%
SummaryUpdated Sep 1, 2026
Replimune Group, Inc. (NASDAQ:REPL) is a clinical-stage biotechnology company founded in 2015 and headquartered in Woburn, Massachusetts. The company went public in July 2018 and specializes in developing oncolytic immuno-gene therapies, a cutting-edge approach to cancer treatment that uses genetically modified viruses to selectively target and destroy cancer cells while simultaneously activating the patient's immune system. Replimune is currently preparing for the potential commercial launch of its lead product candidate RP1, which has received breakthrough therapy designation from the FDA and has a Prescription Drug User Fee Act (PDUFA) date of July 22, 2025.
Similar companies
Latest newsMore news →
Replimune Group, Inc. announced that it will host a conference call on October 28, 2026, to discuss its fiscal second-quarter 2027 financial results and provide a corporate update.13d agoReplimune announced that TUDRIQEV is now available in the U.S. for advanced melanoma, supported by the ReplimuneConnect Plus patient access program.34d agoA class action was filed on behalf of investors who purchased Replimune Group, Inc. (NASDAQ: REPL) securities between October 20, 2025 and April 10, 2026, with a lead plaintiff deadline of October 5, 2026.47d ago